CETUXIMAB , MK-1084, MK-1084, MK-1084, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN , PEMETREXED , MK-1084
MK-3475-01J
Phase 2 small_molecule active
Quick answer
CETUXIMAB , MK-1084, MK-1084, MK-1084, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN , PEMETREXED , MK-1084 for Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active